Please ensure Javascript is enabled for purposes of website accessibility

A Biofuel Shell-ter

By Toby Shute – Updated Apr 6, 2017 at 2:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Big Oil once again plays start-up sugar daddy.

As if the implosion of pure-play ethanol players weren't enough, the broader market meltdown has really put biofuel IPOs on the back burner. First, biodiesel producer Imperium Renewables pulled its planned public offering in early 2008. Several months later, a firm called Codexis withdrew its own proposed IPO.

Silicon Valley start-up Codexis is in the business of cooking up catalysts that enable the production of next-generation biofuels from nonfood sources. That puts the firm up against titans like DuPont (NYSE:DD), BP (NYSE:BP), and Chevron (NYSE:CVX), not to mention hot start-ups like Mascoma and Coskata, in the race to most effectively turn biomass into sugar-derived ethanol. Codexis clearly needs a sugar daddy.

Conveniently, the company counts Royal Dutch Shell (NYSE:RDS-A) (NYSE:RDS-B) -- not to mention Chevron and Pfizer -- as an early investor. Shell, which made its first investment back in 2007, must like what it sees, for The Hague-based heavyweight has upped its stake in Codexis, and is accelerating its drive to commercialize a cellulosic ethanol production process already in demo-mode in Canada.

With the debt markets reeling, and confidence waning in the ability of the venture capital industry to maintain the momentum in greentech, that leaves Big Oil and other multinationals to pick up the slack. Compared to their massive exploration and development budgets, these sorts of investments may strike some skeptics as mere greenwashing, but folks like ConocoPhillips (NYSE:COP) and Petrobras (NYSE:PBR) may be biofuels' best hope.

Pfizer is an Inside Value pick. Petrobras is an Income Investor selection, where Pfizer used to be a recommendation. See what any of our newsletters have cooking with a free 30-day trial.

Fool contributor Toby Shute doesn't have a position in any company mentioned. The Motley Fool's disclosure policy never gets withdrawn.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Royal Dutch Shell plc Stock Quote
Royal Dutch Shell plc
RDS.A
Royal Dutch Shell plc Stock Quote
Royal Dutch Shell plc
RDS.B
BP p.l.c. Stock Quote
BP p.l.c.
BP
$28.08 (-8.80%) $-2.71
Chevron Corporation Stock Quote
Chevron Corporation
CVX
$144.77 (-6.53%) $-10.12
ConocoPhillips Stock Quote
ConocoPhillips
COP
$100.59 (-8.60%) $-9.47
E. I. du Pont de Nemours and Company Stock Quote
E. I. du Pont de Nemours and Company
DD
Petroleo Brasileiro S.A. - Petrobras Stock Quote
Petroleo Brasileiro S.A. - Petrobras
PBR
$12.55 (-9.19%) $-1.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.